Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study.

Björn PasternakViktor WintzellBjorn EliassonAnn-Marie SvenssonStefan FranzénSoffia GudbjörnsdottirKristian HveemChristian JonassonMads MelbyeHenrik SvanströmPeter Ueda

Published in: Diabetes care (2020)

In this large cohort of patients seen in routine clinical practice in three countries, use of GLP-1 receptor agonists, as compared with DPP-4 inhibitors, was associated with a reduced risk of serious renal events.

Keyphrases

clinical practice
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes